KonstantinidisI., NadkarniG.N., YacoubR., SahaA., SimoesP., ParikhC.R.Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review.JAMA Intern Med2016; 176: 121–4.
2.
SoxH.C., LewisR.J.Pragmatic trials: practical answers to “real world” questions.JAMA2016; 316: 1205–6.
3.
TorresV.E., ChapmanA.B., DevuystO., GansevoortR.T., GranthamJ.J., HigashiharaE.Tolvaptan in patients with autosomal dominant polycystic kidney disease.N Engl J Med2012; 367: 2407–18.
4.
StrippoliG.F., CraigJ.C., SchenaF.P.The number, quality, and coverage of randomized controlled trials in nephrology.J Am Soc Nephrol2004; 15: 411–9.
5.
ZhangL., BadveS., PascoeE., BellerE., CassA., ClarkC.Representativeness of HONEYPOT trial participants to Australasian PD patients.Perit Dial Int2017; 37(5): 516–22.
6.
JohnsonD.W., BadveS.V., PascoeE.M., BellerE., CassA., ClarkC.Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.Lancet Infect Dis2014; 14: 23–30.
7.
ClarkA.L., LammimanM.J., GoodeK., ClelandJ.G.Is taking part in clinical trials good for your health? A cohort study.Eur J Heart Fail2009; 11: 1078–83.
8.
SullivanJ.Subject recruitment and retention: barriers to success.Appl Clin Trials2004.
9.
ChertowG.M., BlockG.A., Correa-RotterR., DruekeT.B., FloegeJ., GoodmanW.G.Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.N Engl J Med2012; 367: 2482–94.
10.
IsraniA.K., HalpernS.D., McFaddenC., IsraniR.K., WassersteinA., KobrinS.Willingness of dialysis patients to participate in a randomized controlled trial of daily dialysis.Kidney Int2004; 65: 990–8.
11.
ChiuD., GreenD., AbidinN., HughesJ., OduduA., SinhaS.Non-recruitment to and selection bias in studies using echocardiography in hemodialysis patients.Nephrology (Carlton)2016. doi: 10.1111/nep.12865. [Epub ahead of print.]
12.
DeckerE., KendrickJ.Research in the CKD clinic: highs and lows.Adv Chronic Kidney Dis2014; 21: 344–8.
13.
MartinS.S., OuF.S., NewbyL.K., SuttonV., AdamsP., FelkerG.M.Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials.J Am Coll Cardiol2013; 61: 762–9.
14.
VestboJ., LeatherD., Diar BakerlyN., NewJ., GibsonJ.M., McCorkindaleS.Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice.N Engl J Med2016; 375: 1253–60.
15.
ThorpeK.E., ZwarensteinM., OxmanA.D., TreweekS., FurbergC.D., AltmanD.G.A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.J Clin Epidemiol2009; 62: 464–75.
16.
ZwarensteinM., TreweekS., GagnierJ.J., AltmanD.G., TunisS., HaynesB.Improving the reporting of pragmatic trials: an extension of the consort statement.BMJ2008; 337: a2390.
